Wyeth Presents Data from Five-Year Vertebral Fracture Prevention Study with Bazedoxifene
Collegeville, Pennsylvania (ots/PRNewswire) - Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announces findings from a placebo-controlled Phase 3 study of bazedoxifene 20 mg extended to five years, which indicated a significant reduction versus placebo in new vertebral fractures in postmenopausal women with osteoporosis. These and other data were ...